Knee Osteoarthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Knee Osteoarthritis pipeline constitutes 50+ key companies continuously working towards developing 60+ Knee Osteoarthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Knee Osteoarthritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Knee Osteoarthritis Market.

The Knee Osteoarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Knee Osteoarthritis Pipeline Report: https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Knee Osteoarthritis treatment therapies with a considerable amount of success over the years.
• Knee Osteoarthritis companies working in the treatment market are Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others, are developing therapies for the Knee Osteoarthritis treatment
• Emerging Knee Osteoarthritis therapies in the different phases of clinical trials are- M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others are expected to have a significant impact on the Knee Osteoarthritis market in the coming years.
• In May 2025, Lipogems announced the successful completion of its ARISE I U.S. FDA IDE Study, with the final patient visit now concluded. This marks a significant milestone in progressing Lipogems as a treatment option for knee osteoarthritis (OA) in patients who are not eligible for or ready to undergo knee replacement. The double-blind, randomized controlled trial included 173 participants across 18 leading U.S. clinical sites. The study's primary focus is on assessing pain relief and functional improvement 12 months after injection. Results on efficacy and safety are anticipated by late 2025.
• In May 2025, Genascence Corporation, a clinical-stage biotech firm focused on transforming musculoskeletal disease treatment through gene therapy, reported positive 12-month safety and biomarker findings from its Phase 1b DONATELLO trial of GNSC-001. This investigational gene therapy targets interleukin 1 (IL-1) for treating knee osteoarthritis (OA). The 12-month results confirmed the trial met its primary endpoint, showing consistent safety and tolerability across all tested doses. Additionally, the study met a key secondary endpoint, demonstrating sustained IL-1Ra expression in synovial fluid, reinforcing the six-month data previously reported.
• In May 2025, Moximed, a pioneering medical device company focused on enhancing care for individuals with knee osteoarthritis (OA), announced that the first patients have been treated in its latest randomized controlled trial (RCT). The MOTION study is a prospective, multicenter trial designed to compare the effectiveness of the MISHA Knee System against non-surgical treatment options in patients with medial knee osteoarthritis.
• In April 2025, Pacira BioSciences reported that its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), showed long-lasting improvements in knee pain, mobility, and stiffness for up to two years in a Phase I trial. Participants received a single local injection of the therapy. The study included 72 individuals aged 30 to 80, categorized based on the severity of their knee osteoarthritis using the Kellgren-Lawrence (K/L) grading system.
• In April 2025, Israel-based Enlivex Therapeutics announced the completion of enrollment for the Phase II portion of its Phase I/II trial evaluating Allocetra, an off-the-shelf cell therapy for moderate to severe knee osteoarthritis. In this phase, over 133 subjects were randomized and treated. The multi-center, randomized trial is divided into two stages, with Phase I being an open-label, dose-escalation study focused on assessing the safety and tolerability of Allocetra injections into the knee.
• In March 2025, RION, a clinical-stage company specializing in regenerative medicine and exosome-based therapies, announced the enrollment of the first patient in its Phase 1b trial of Purified Exosome ProductTM (PEPTM) for treating Knee Osteoarthritis (OA). This marks a significant step in RION's mission to develop cutting-edge regenerative solutions for unmet medical needs.
• In September 2024, Cytonics announced the completion of patient enrollment in a Phase I clinical trial for CYT-108, which is being investigated as a potential disease-modifying therapy for knee osteoarthritis (OA). CYT-108 is a recombinant variant of the alpha-2-macroglobulin blood serum protease inhibitor.

Knee Osteoarthritis Overview
Knee osteoarthritis is a degenerative joint disease where the cartilage in the knee gradually wears down, leading to pain, stiffness, swelling, and reduced mobility. It commonly affects older adults and can be caused by aging, joint injury, obesity, or genetics. As the protective cartilage erodes, bones may rub together, causing further damage. Treatment includes physical therapy, medications, lifestyle changes, and in severe cases, knee replacement surgery.

Get a Free Sample PDF Report to know more about Knee Osteoarthritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/knee-osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Knee Osteoarthritis Drugs Under Different Phases of Clinical Development Include:
• M6495: Merck KGaA
• PPV 06: Peptinov
• LG00034053: LG Chem
• StroMel: Akan Bioscience
• TTAX03: BioTissue,Inc.
• EP-104IAR: Eupraxia Pharmaceuticals Inc.
• OLP 1002: OliPass Corporation
• JTA-004: Bone Therapeutics
• X 0002: Techfields Pharma
• Lorecivivint: Biosplice Therapeutics

Knee Osteoarthritis Route of Administration
Knee Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Knee Osteoarthritis Molecule Type
Knee Osteoarthritis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Knee Osteoarthritis Pipeline Therapeutics Assessment
• Knee Osteoarthritis Assessment by Product Type
• Knee Osteoarthritis By Stage and Product Type
• Knee Osteoarthritis Assessment by Route of Administration
• Knee Osteoarthritis By Stage and Route of Administration
• Knee Osteoarthritis Assessment by Molecule Type
• Knee Osteoarthritis by Stage and Molecule Type

DelveInsight's Knee Osteoarthritis Report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Knee Osteoarthritis product details are provided in the report. Download the Knee Osteoarthritis pipeline report to learn more about the emerging Knee Osteoarthritis therapies
https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Knee Osteoarthritis Therapeutics Market include:
Key companies developing therapies for Knee Osteoarthritis are - Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others.

Knee Osteoarthritis Pipeline Analysis:
The Knee Osteoarthritis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Knee Osteoarthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Knee Osteoarthritis Treatment.
• Knee Osteoarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Knee Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Knee Osteoarthritis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Knee Osteoarthritis drugs and therapies
https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Knee Osteoarthritis Pipeline Market Drivers
• Increase in prevalence of Osteoarthritis, robust Knee Osteoarthritis Pipeline are some of the important factors that are fueling the Knee Osteoarthritis Market.

Knee Osteoarthritis Pipeline Market Barriers
• However, risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment, high cost associated with the treatment and other factors are creating obstacles in the Knee Osteoarthritis Market growth.

Scope of Knee Osteoarthritis Pipeline Drug Insight
• Coverage: Global
• Key Knee Osteoarthritis Companies: Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others
• Key Knee Osteoarthritis Therapies: M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others
• Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies
• Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.